Search for in this collection

Subscribe to this collection to receive daily e-mail notification of new additions

Preview	Issue Date	Title / Name	Author(s)
	Aug-2023	First-line, fixed-duration nivolumab plus ipilimumab followed by nivolumab in clinically diverse patient populations with unresectable stage III or IV melanoma: Checkmate 401	Dummer, R.; Corrie, P; Gutzmer, R.; Meniaway, T. M.; Del Vecchio, M.; Lebbe, C; Guida, M.; Dutriaux, C.; Dreno, B.; Meyer, N.; Ferrucci, P. F.; Dalle, S.; Khattak, M. A.; Grob, J.-J.; Briscoe, K.; Larkin, J.; Mansard, S.; Lesimple, T.; Guidoboni, M.; Sabatini, S.; Richtig, E.; Herbst, R.; Lobo, M.; Askelson, M.; Ascierto, P. A.; Maio, M.; Briscoe, Karen
	Feb-2016	Testing the assessment of new radiation oncology technology and treatments framework using the evaluation of post-prostatectomy radiotherapy techniques.	Duchesne, G. M.; Harworth, A.; Bone, E.; Carter, H.; Ebert, M. A.; Gagliardi, F.; Gibbs, A.; Hornby, C.; Martin, A.; Sidhom, M.; Wood, M.; Jackson, M.; Wood, Maree
	May-2023	Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?	Dubrava, A. L.; Kyaw, P. S. P.; Newman, J.; Pringle, J.; Westhuyzen, J.; Fuentes, G. L. H.; Shakespeare, T. P.; Sakalkale, R.; Aherne, N. J.; Dubrava, Alex L.; Kyaw, Pan Su Pyae; Newman, Joseph; Pringle, Jarrad; Shakespeare, Thomas P.; Sakalkale, Renukadas; Aherne, Noel
	May-2024	Serrated polyposis syndrome: defining the epidemiology and predicting the risk of dysplasia	Dierick, N. R.; Nicholson, B. D.; Fanshawe, T. R.; Sundaralingam, P.; Dierick, Natalie R.; Sundaralingam, Praka
	Jan-2015	Vulvovaginal pyoderma gangrenosum secondary to rituximab therapy	Dixit, S.; Selva-Nayagam, P.; Hamann, I.; Fischer, G.; Hamann, Ian
	Sep-2023	Surgery at specialised sarcoma centres improves patient outcomes - A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party.	Hong, A.M.; Sundaram, A.; Perianayagam, G.; Lo, H.; Lawless, A.; Zhou, D.; McDonough, J.; Thompson, S.R.; Maclean, F.; Connolly, E.A.; Coker, D.; Mar, J.; Lazarakis, S.; Johnston, A.; Lo, H.
	Dec-2022	The benefit for radiotherapy at specialised sarcoma centres: A systematic review and clinical practice guidelines from the Australia and New Zealand Sarcoma Association.	Hong, A.M.; Lo, H.; Lawless, A.; Zhou, D.; Bae, S.; Phillips, M.; Maclean, F.; Desai, J.; Mar, J.; Lazarakis, S.; Pryor, D.; Thompson, S.R.; Australia and New Zealand Sarcoma Association Guidelines Working Party; Lo, H.
	Jul-2020	A critical literature review on the use of bellyboard devices to control small bowel dose for pelvic radiotherapy.	Hoffmann, Matthew; Waller, K.; Last, Andrew; Westhuyzen, Justin; Hoffmann, Matthew; Waller, K.; Last, Andrew; Westhuyzen, Justin
	Nov-2018	Analysis of a volumetric-modulated arc therapy (VMAT) single phase prostate template as a class solution.	Hoffmann, Matthew; Pacey, J.; Goodworth, J.; Laszcyzk, A.; Ford, R.; Chick, Brendan; Greenham, Stuart; Westhuyzen, Justin; Hoffmann, Matthew; Pacey, J.; Goodworth, J.; Chick, Brendan; Greenham, Stuart; Westhuyzen, Justin
	Jul-2021	Equity should know no borders: The role of Australasian radiation oncologists in supporting radiation oncology services in low- and middle-income countries in the Asia-Pacific.	Hassan, S.; Oar, A.; Ward, I.; Koh, E.S.; Shakespeare, T.; Yap, M.L.; Shakespeare, Thomas P.
	Jul-2020	Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors	Desai, J.; Gan, H.; Barrow, C.; Jameson, M.; Atkinson, V.; Haydon, A.; Millward, M.; Begbie, S.; Brown, M.; Markman, B.; Patterson, W.; Hill, A.; Horvath, L.; Nagrial, A.; Richardson, G.; Jackson, C.; Friedlander, M.; Parente, P,; Tran, B.; Wang, L.; Chen, Y.; Tang, Z.; Huang, W.; Wu, J.; Zeng, D.; Luo, L.; Solomon, B.; Begbie, Stephen
	Sep-2021	Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy	Sweeney, C. J.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Chi, K. N.; Chowdhury, S.; Coskinas, X; Frydenberg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G. M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Tu, E.; Vera-Badillo, F.; Williams, S. G.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Davis, I. D.; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP); Begbie, Stephen
	Apr-2023	Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial	Sweeney, C. J.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Cheung, L.; Chi, K. N.; Chowdhury, S.; Frydenberg, M.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Vera-Badillo, F.; Williams, S. G.; Winter, D.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Davis, I. D.; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Begbie, Stephen
	Mar-2022	Health-related quality of life in metastatic hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international randomized phase III trial led by ANZUP	Stockler, M. R.; Martin, A. J.; Davis, I. D.; Dhillon, H. M.; Begbie, S. D.; Chi, K. N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G. M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W. R.; Pook, D. W.; Reaume, M. N.; Sandhu, S.; Tan, A.; Tan, T. H.; Thomson, A.; Vera-Badillo, F.; Williams, S. G.; Winter, D. G.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Sweeney, C. J.; ENSAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Begbie, Stephen
	Aug-1995	Hypofractionated irradiation for inoperable non-small cell lung cancer	Stevens, M. J.; Begbie, S. D.; Begbie, Stephen
	Jul-2013	Decision regret in men undergoing dose-escalated radiation therapy for prostate cancer	Steer, A. N.; Aherne, N. J.; Hoffmann, M.; Last, A.; Hill, J.; Shakespeare, T. P.; Steer, Anna N.; Aherne, Noel; Hoffmann, Matthew; Last, Andrew; Hill, Jacques; Shakespeare, Thomas P.
	Apr-2015	Use of oral formulations of fentanyl for breakthrough cancer pain	Handsaker, Scott; Dempsey, L.; Fabby, C.; Handsaker, Scott
	Feb-2021	Assessment of genetic referrals and outcomes for women with triple negative breast cancer in regional cancer centres in Australia.	Hallenstein, L.; Sorensen, C.; Hodgson, L.; Wen, S.; Westhuyzen, J.; Hansen, C.; Last, A.; Amalaseelan, J.V.; Salindera, S.; Ross, W.; Spigelman, A.D.; Shakespeare, T.; Aherne, N.; Hallenstein, L.; Sorensen, C.; Wen, S.; Westhuyzen, Justin; Hansen, Carmen; Last, Andrew; Shakespeare, Thomas P.; Aherne, Noel
	Oct-2022	Exploring cancer patients', caregivers', and clinicians' utilisation and experiences of telehealth services during COVID-19: A qualitative study	Smith, S. J.; Smith, A. B.; Kennett, W.; Vinod, S. K.; Kennett, William
	Nov-2017	Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning.	Gupta, S.K.; Watson, T.; Denham, J.; Shakespeare, T.; Rutherford, N.; McLeod, N.; Picton, K.; Ainsworth, P.; Bonaventura, T.; Martin, J.M.; Shakespeare, Thomas P.